Literature DB >> 22024423

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?

F Strittmatter1, P Stieber, D Nagel, C Füllhase, S Walther, C G Stief, R Waidelich.   

Abstract

OBJECTIVE: To evaluate the performance of total PSA (tPSA), the free/total PSA ratio (f/tPSA), complexed PSA (cPSA) and the complexed/total PSA ratio (c/tPSA) in prostate cancer detection.
METHODS: Frozen sera of 442 patients have been analysed for tPSA, free PSA (fPSA) and cPSA. 131 patients had prostate cancer and 311 patients benign prostatic hyperplasia.
RESULTS: Differences in the distribution of the biomarkers were seen as follows: tPSA, cPSA and c/tPSA were significantly higher in the PC group, and f/tPSA was significantly higher in the BPH group. In the tPSA-range of 0-4 ng/ml none of the biomarkers showed a significant difference in the distribution between both groups. In the tPSA-ranges of 0-10 ng/ml, 2-10 ng/ml, 4-10 ng/ml and <10 ng/ml, f/tPSA showed the highest specificity at high sensitivtities, followed by c/tPSA, cPSA, and tPSA, respectively. In tPSA-ranges greater than 10 ng/ml, cPSA offered the best discriminatory ability. CPSA compared to tPSA offered better specificity at high sensitivities in all tPSA-ranges.
CONCLUSION: F/tPSA offers the best ability to distinguish between both groups in lower tPSA-ranges, followed by c/tPSA. CPSA compared to tPSA offers a better ability to discriminate between both groups in all PSA-ranges and could be used as an initial test for PC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22024423      PMCID: PMC3400975          DOI: 10.1186/2047-783x-16-10-445

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  29 in total

1.  Is free prostate-specific antigen helpful in the differential diagnosis of benign hyperplasia and cancer of the prostate?

Authors:  W Reiter; P Stieber; N Schmeller; D Nagel; C Schambeck; A Fateh-Moghadam
Journal:  Tumour Biol       Date:  1997

Review 2.  [EAU guidelines on prostate cancer].

Authors:  Axel Heidenreich; Gunna Aus; Michel Bolla; Steven Joniau; Vsevolod B Matveev; Hans Peter Schmid; Filliberto Zattoni
Journal:  Actas Urol Esp       Date:  2009-02       Impact factor: 0.994

3.  Screening for prostate cancer.

Authors:  W J Catalona
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

4.  Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?

Authors:  K Jung; U Elgeti; M Lein; B Brux; P Sinha; B Rudolph; S Hauptmann; D Schnorr; S A Loening
Journal:  Clin Chem       Date:  2000-01       Impact factor: 8.327

5.  Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays.

Authors:  R Junker; B Brandt; C Zechel; G Assmann
Journal:  Clin Chem       Date:  1997-09       Impact factor: 8.327

6.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

Authors:  W J Catalona; D S Smith; D K Ornstein
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

7.  Role of PSA and its indices in determining the need for repeat prostate biopsies.

Authors:  O Ukimura; O Durrani; R J Babaian
Journal:  Urology       Date:  1997-07       Impact factor: 2.649

8.  Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.

Authors:  M K Brawer; C D Cheli; I E Neaman; J Goldblatt; C Smith; M K Schwartz; D J Bruzek; D L Morris; L J Sokoll; D W Chan; K K Yeung; A W Partin; W J Allard
Journal:  J Urol       Date:  2000-05       Impact factor: 7.450

9.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.

Authors:  U H Stenman; J Leinonen; H Alfthan; S Rannikko; K Tuhkanen; O Alfthan
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

10.  Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men?

Authors:  Koji Okihara; Osamu Ukimura; Terukazu Nakamura; Yoichi Mizutani; Akihiro Kawauchi; Yoshio Naya; Mutsumi Uchida; Takahiro Ogiwara; Tsuneharu Miki
Journal:  Eur Urol       Date:  2004-07       Impact factor: 20.096

View more
  3 in total

1.  Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen.

Authors:  Jiang Feng; Feng Gang; Xiao Li; Tang Jin; Huang Houbao; Cao Yu; Li Guorong
Journal:  Int Urol Nephrol       Date:  2013-06-19       Impact factor: 2.370

Review 2.  Sarcosine as a potential prostate cancer biomarker--a review.

Authors:  Natalia Cernei; Zbynek Heger; Jaromir Gumulec; Ondrej Zitka; Michal Masarik; Petr Babula; Tomas Eckschlager; Marie Stiborova; Rene Kizek; Vojtech Adam
Journal:  Int J Mol Sci       Date:  2013-07-04       Impact factor: 5.923

Review 3.  Prognostic and predictive biomarkers: tools in personalized oncology.

Authors:  Ewelina Nalejska; Ewa Mączyńska; Marzena Anna Lewandowska
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.